Publications

2023

1. A tutorial on time-dependent cohort state-transition models in R using a cost-effectiveness analysis example

   Fernando Alarid-Escudero, Eline Krijkamp, Eva A Enns, Alan Yang, MG Myriam Hunink, Petros Pechlivanoglou, and Hawre Jalal

   Medical Decision Making, 2023
2. An introductory tutorial on cohort state-transition models in R using a cost-effectiveness analysis example

   Fernando Alarid-Escudero, Eline Krijkamp, Eva A Enns, Alan Yang, MG Myriam Hunink, Petros Pechlivanoglou, and Hawre Jalal

   Medical Decision Making, 2023
3. Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program

   Yuliia Sereda, Fernando Alarid-Escudero, Nina A Bickell, Su-Hsin Chang, Graham A Colditz, Chin Hur, Hawre Jalal, Evan R Myers, Tracy M Layne, Shi-Yi Wang, and  others

   JNCI Monographs, 2023

2022

1. Exponential growth of drug overdose poisoning and opportunities for intervention

   Hawre Jalal, and Donald S Burke

   Addiction, 2022
2. Reply commentary by Jalal and Burke.

   Donald S Burke, and Hawre Jalal

   The International Journal on Drug Policy, 2022
3. APCtools: Descriptive and Model-based Age-Period-Cohort Analysis

   Alexander Bauer, Maximilian Weigert, and Hawre Jalal

   Journal of Open Source Software, 2022

2021

1. 

   BayCANN: streamlining Bayesian calibration with artificial neural network metamodeling

   Hawre Jalal, Thomas A Trikalinos, and Fernando Alarid-Escudero

   Frontiers in Physiology, 2021
2. Carfentanil and the rise and fall of overdose deaths in the United States

   Hawre Jalal, and Donald S Burke

   Addiction, 2021
3. Microsimulation model to compare enteral and parenteral iron supplementation in children with intestinal failure

   Vikram Kalathur Raghu, Jeffrey A Rudolph, Hawre J Jalal, and Kenneth J Smith

   Journal of Parenteral and Enteral Nutrition, 2021
4. Future projection of the health and functional status of older people in Japan: A multistate transition microsimulation model with repeated cross-sectional data

   Megumi Kasajima, Hideki Hashimoto, Sze-Chuan Suen, Brian Chen, Hawre Jalal, Karen Eggleston, and Jay Bhattacharya

   Health Economics, 2021
5. Data needs in opioid systems modeling: challenges and future directions

   Mohammad S Jalali, Emily Ewing, Calvin B Bannister, Lukas Glos, Sara Eggers, Tse Yang Lim, Erin Stringfellow, Celia A Stafford, Rosalie Liccardo Pacula, Hawre Jalal, and  others

   American journal of preventive medicine, 2021
6. Towards a Public Health Approach to Homicides in Mexico

   Andrea Luviano, Hawre Jalal, Alfonso Miranda, Alejandro Madrazo, Michael Reich, and Fernando Alarid-Escudero

   Available at SSRN 3795313, 2021
7. Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? A value of information analysis

   Angela R Wateska, Mary Patricia Nowalk, Hawre Jalal, Chyongchiou J Lin, Lee H Harrison, William Schaffner, Richard K Zimmerman, and Kenneth J Smith

   Vaccine, 2021
8. How simulation modeling can support the public health response to the opioid crisis in North America: setting priorities and assessing value

   Nicholas J Bansback, Carolina Barbosa, Joshua Barocas, Ahmed M Bayoumi, Czarina Behrends, Jag Chhatwal, Lauren E Cipriano, Phillip Coffin, Jeremy Goldhaber-Fiebert, Jeffrey S Hoch, and  others

   International Journal of Drug Policy, 2021
9. Prominent spatiotemporal waves of COVID-19 incidence in the United States: Implications for causality, forecasting, and control

   Hawre Jalal, Kyueun Lee, and Donald S Burke

   medRxiv, 2021
10. Recurring Spatiotemporal Patterns of COVID-19 in the United States

    Hawre Jalal, Kyueun Lee, and Donald S Burke

    medRxiv, 2021

2020

1. 

   Age and generational patterns of overdose death risk from opioids and other drugs

   Hawre Jalal, Jeanine M Buchanich, David R Sinclair, Mark S Roberts, and Donald S Burke

   Nature medicine, 2020
2. Calculating the expected value of sample information in practice: considerations from 3 case studies

   Anna Heath, Natalia Kunst, Christopher Jackson, Mark Strong, Fernando Alarid-Escudero, Jeremy D Goldhaber-Fiebert, Gianluca Baio, Nicolas A Menzies, and Hawre Jalal

   Medical Decision Making, 2020
3. A multidimensional array representation of state-transition model dynamics

   Eline M Krijkamp, Fernando Alarid-Escudero, Eva A Enns, Petros Pechlivanoglou, MG Myriam Hunink, Alan Yang, and Hawre J Jalal

   Medical Decision Making, 2020
4. Associations between the specialty of opioid prescribers and opioid addiction, misuse, and overdose outcomes

   Carroline P Lobo, Gerald Cochran, Chung-Chou H Chang, Walid F Gellad, Adam J Gordon, Hawre Jalal, Wei-Hsuan Lo-Ciganic, Jordan F Karp, David Kelley, and Julie M Donohue

   Pain Medicine, 2020
5. Computing PROPr utility scores for PROMIS\textregistered profile instruments

   Barry Dewitt, Hawre Jalal, and Janel Hanmer

   Value in Health, 2020
6. Computing the expected value of sample information efficiently: practical guidance and recommendations for four model-based methods

   Natalia Kunst, Edward CF Wilson, David Glynn, Fernando Alarid-Escudero, Gianluca Baio, Alan Brennan, Michael Fairley, Jeremy D Goldhaber-Fiebert, Chris Jackson, Hawre Jalal, and  others

   Value in Health, 2020
7. Developing and validating metamodels of a microsimulation model of infant HIV testing and screening strategies used in a decision support tool for health policy makers

   Djøra I Soeteman, Stephen C Resch, Hawre Jalal, Caitlin M Dugdale, Martina Penazzato, Milton C Weinstein, Andrew Phillips, Taige Hou, Elaine J Abrams, Lorna Dunning, and  others

   MDM Policy & Practice, 2020
8. Dissemination science to advance the use of simulation modeling: our obligation moving forward

   Bohdan Nosyk, Janet Weiner, Emanuel Krebs, Xiao Zang, Benjamin Enns, Czarina N Behrends, Daniel J Feaster, Hawre Jalal, Brandon DL Marshall, Ankur Pandya, and  others

   Medical Decision Making, 2020
9. Hexamaps for age-period-cohort data visualization and implementation in R

   Hawre Jalal, and Donald S Burke

   Epidemiology (Cambridge, Mass.), 2020
10. Prioritizing additional data collection to reduce decision uncertainty in the HIV/AIDS response in 6 US cities: a value of information analysis

    Xiao Zang, Hawre Jalal, Emanuel Krebs, Ankur Pandya, Haoxuan Zhou, Benjamin Enns, and Bohdan Nosyk

    Value in Health, 2020

2019

1. The curve of optimal sample size (COSS): a graphical representation of the optimal sample size from a value of information analysis

   Eric Jutkowitz, Fernando Alarid-Escudero, Karen M Kuntz, and Hawre Jalal

   Pharmacoeconomics, 2019
2. “Time traveling is just too dangerous” but some methods are worth revisiting: the advantages of expected loss curves over cost-effectiveness acceptability curves and frontier

   Fernando Alarid-Escudero, Eva A Enns, Karen M Kuntz, Tzeyu L Michaud, and Hawre Jalal

   Value in Health, 2019
3. A need for change! A coding framework for improving transparency in decision modeling

   Fernando Alarid-Escudero, Eline M Krijkamp, Petros Pechlivanoglou, Hawre Jalal, Szu-Yu Zoe Kao, Alan Yang, and Eva A Enns

   Pharmacoeconomics, 2019

2018

1. 

   Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016

   Hawre Jalal, Jeanine M Buchanich, Mark S Roberts, Lauren C Balmert, Kun Zhang, and Donald S Burke

   Science, 2018

2. 

   A Gaussian approximation approach for value of information analysis

   Hawre Jalal, and Fernando Alarid-Escudero

   Medical Decision Making, 2018
3. Microsimulation modeling for health decision sciences using R: a tutorial

   Eline M Krijkamp, Fernando Alarid-Escudero, Eva A Enns, Hawre J Jalal, MG Myriam Hunink, and Petros Pechlivanoglou

   Medical Decision Making, 2018

2017

1. An overview of R in health decision sciences

   Hawre Jalal, Petros Pechlivanoglou, Eline Krijkamp, Fernando Alarid-Escudero, Eva Enns, and MG Myriam Hunink

   Medical decision making, 2017
2. Prioritizing future research on allopurinol and febuxostat for the management of gout: value of information analysis

   Eric Jutkowitz, Fernando Alarid-Escudero, Hyon K Choi, Karen M Kuntz, and Hawre Jalal

   Pharmacoeconomics, 2017
3. Opportunity Cost Of Non-Rigorous Or Non-Transferable Research: Implications For Cost-Effectiveness Analysis

   F Alarid-Escudero, H Jalal, and TA Trikalinos

   Value in Health, 2017

2016

1. 

   Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis

   Hawre Jalal, James R O’Dell, S Louis Bridges Jr, Stacey Cofield, Jeffrey R Curtis, Ted R Mikuls, Larry W Moreland, and Kaleb Michaud

   Arthritis care & research, 2016
2. Some health states are better than others: using health state rank order to improve probabilistic analyses

   Jeremy D Goldhaber-Fiebert, and Hawre J Jalal

   Medical Decision Making, 2016
3. Forecasting trends in disability in a super-aging society: adapting the future elderly model to Japan

   Brian K Chen, Hawre Jalal, Hideki Hashimoto, Sze-chuan Suen, Karen Eggleston, Michael Hurley, Lena Schoemaker, and Jay Bhattacharya

   The Journal of the Economics of Ageing, 2016

2015

1. Computing expected value of partial sample information from probabilistic sensitivity analysis using linear regression metamodeling

   Hawre Jalal, Jeremy D Goldhaber-Fiebert, and Karen M Kuntz

   Medical Decision Making, 2015
2. Cost-effectiveness of a statewide campaign to promote aspirin use for primary prevention of cardiovascular disease

   Tzeyu L Michaud, Jean Abraham, Hawre Jalal, Russell V Luepker, Sue Duval, and Alan T Hirsch

   Journal of the American Heart Association, 2015
3. Automating identification of multiple chronic conditions in clinical practice guidelines

   Tiffany I Leung, Hawre Jalal, Donna M Zulman, Michel Dumontier, Douglas K Owens, Mark A Musen, and Mary K Goldstein

   AMIA Summits on Translational Science Proceedings, 2015

2013

1. 

   Linear regression metamodeling as a tool to summarize and present simulation model results

   Hawre Jalal, Bryan Dowd, François Sainfort, and Karen M Kuntz

   Medical Decision Making, 2013

2012

1. Network meta-analysis of margin threshold for women with ductal carcinoma in situ

   Shi-Yi Wang, Haitao Chu, Tatyana Shamliyan, Hawre Jalal, Karen M Kuntz, Robert L Kane, and Beth A Virnig

   Journal of the National Cancer Institute, 2012

2011

1. Including indirect medical care costs from survivor years of life in economic evaluations

   John A Nyman, and Hawre J Jalal

   Pharmacoeconomics, 2011